Bausch + Lomb new scientific and clinical analyses presented at ARVO meeting

Researchers have presented the results of nine Bausch + Lomb new scientific and clinical analyses involving its Pharmaceutical and Surgical products, plus data from its Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, at the 2019 Association for Research in Vision and Ophthalmology (ARVO) meeting in Vancouver.
The ARMOR study analyses included a ten-year trend analysis, examining antibiotic resistance trends among staphylococcal isolates collected in the ARMOR study to date, as well as a preliminary analysis of the 2018 ARMOR results. There was integrated data from three Phase 3 multicenter, randomized, double-masked clinical trials on the proportion of subjects achieving zero-trace anterior chamber inflammation with the company’s new submicron loteprednol formulation, LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%, following cataract surgery, as well as pooled data from three multicenter, randomized clinical studies analyzing the incidence of polybacterial infections in bacterial conjunctivitis and outcomes using besifloxacin ophthalmic suspension 0.6%. There was also an assessment utilizing the eyeTELLIGENCE™ platform on the Stellaris Elite™ vision enhancement system to measure the relative effect of gauge size and surgeon efficiency during vitrectomy surgeries, as well as research regarding future intraocular lens designs, next-generation delivery systems and product enhancements.
Joe Gordon, U.S. president, Bausch + Lomb, said: “Bausch + Lomb is deeply committed to supporting continued research on our product portfolio in order to provide practitioners with new information that can help inform their treatment decisions. Doing so is part of our commitment to better address the needs of their patients for today and tomorrow.”